159 related articles for article (PubMed ID: 34848114)
1. Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae.
Mariani LG; Ferreira LM; Rovaris DL; Bonamigo RR; Kiszewski AE
An Bras Dermatol; 2022; 97(1):37-44. PubMed ID: 34848114
[TBL] [Abstract][Full Text] [Related]
2. Predictors of poor response to oral propranolol in infantile hemangiomas.
Hali F; Moubine I; Berrami H; Serhier Z; Othmani MB; Chiheb S
Arch Pediatr; 2023 Oct; 30(7):455-457. PubMed ID: 37394367
[TBL] [Abstract][Full Text] [Related]
3. Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.
McCormick AA; Tarchichi T; Azbell C; Grunwaldt L; Jabbour N
Int J Pediatr Otorhinolaryngol; 2018 Oct; 113():34-37. PubMed ID: 30174006
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
Sagi L; Zvulunov A; Lapidoth M; Ben Amitai D
Dermatology; 2014; 228(2):136-44. PubMed ID: 24556822
[TBL] [Abstract][Full Text] [Related]
5. [Infantile hemangiomas: the revolution of beta-blockers].
Leaute-Labreze C
Rev Prat; 2014 Dec; 64(10):1421-8. PubMed ID: 25665327
[TBL] [Abstract][Full Text] [Related]
6. Propranolol for infantile hemangiomas.
Bagazgoitia L; Torrelo A; Gutiérrez JC; Hernández-Martín A; Luna P; Gutiérrez M; Baño A; Tamariz A; Larralde M; Alvarez R; Pardo N; Baselga E
Pediatr Dermatol; 2011; 28(2):108-14. PubMed ID: 21385205
[TBL] [Abstract][Full Text] [Related]
7. Recurrence rate of infantile hemangioma after oral propranolol therapy.
Frongia G; Byeon JO; Mehrabi A; Günther P
Eur J Pediatr; 2021 Feb; 180(2):585-590. PubMed ID: 33188478
[TBL] [Abstract][Full Text] [Related]
8. Management of infantile hemangiomas-experience of a tertiary hospital.
Gomes R; Salazar L; Fraga C; Correia MR; Barbosa-Sequeira J; Fernandes A; Álvares S; Banquart Leitão J; Paiva Coelho M
Eur J Pediatr; 2023 Apr; 182(4):1611-1618. PubMed ID: 36705724
[TBL] [Abstract][Full Text] [Related]
9. Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.
Wang L; Li S; Gao Q; Lv R; Xu G; Li X; Bi J; Huo R
Head Neck; 2021 May; 43(5):1553-1562. PubMed ID: 33539620
[TBL] [Abstract][Full Text] [Related]
10. Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment.
Kagami S; Kaneko M; Kishi A; Katori T
J Dermatol; 2018 Sep; 45(9):1109-1112. PubMed ID: 29952019
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics of infantile hemangiomas with aggressive, persistent, and destructive ulceration.
Gautam A; Frieden IJ; Shah SD; Witman PM; Harfmann K; Bradley F; Blei F; Pope E; Alsumait A; Gupta D; Covelli I; Streicher JL; Cotton C; Tollefson M; Nguyen H; Hunt R; Buros A; Fernández Faith E
Pediatr Dermatol; 2023; 40(6):996-1002. PubMed ID: 37845188
[TBL] [Abstract][Full Text] [Related]
12. Early propranolol treatment of infantile hemangiomas improves outcome.
Giachetti A; Díaz MS; Boggio P; Posadas Martínez ML
An Bras Dermatol; 2023; 98(3):310-315. PubMed ID: 36577593
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Clinical Outcomes of Parotid Hemangiomas in the Pediatric Patient Population.
Harris J; Phillips JD
Ear Nose Throat J; 2021 Jun; 100(5):NP242-NP245. PubMed ID: 31565986
[TBL] [Abstract][Full Text] [Related]
14. Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: A long-term follow-up study.
Yu Z; Cai R; Chang L; Qiu Y; Chen X; Chen Q; Ma G; Jin Y; Lin X
J Dermatol; 2019 May; 46(5):376-382. PubMed ID: 30916822
[TBL] [Abstract][Full Text] [Related]
15. Growth characteristics of infantile hemangiomas: implications for management.
Chang LC; Haggstrom AN; Drolet BA; Baselga E; Chamlin SL; Garzon MC; Horii KA; Lucky AW; Mancini AJ; Metry DW; Nopper AJ; Frieden IJ;
Pediatrics; 2008 Aug; 122(2):360-7. PubMed ID: 18676554
[TBL] [Abstract][Full Text] [Related]
16. Segmental hemangioma of infancy complicated by life-threatening arterial bleed.
Connelly EA; Viera M; Price C; Waner M
Pediatr Dermatol; 2009; 26(4):469-72. PubMed ID: 19689527
[TBL] [Abstract][Full Text] [Related]
17. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls.
Hermans DJ; van Beynum IM; Schultze Kool LJ; van de Kerkhof PC; Wijnen MH; van der Vleuten CJ
J Am Acad Dermatol; 2011 May; 64(5):833-8. PubMed ID: 21353329
[TBL] [Abstract][Full Text] [Related]
18. Retrospective case series of increased oral propranolol dosage for infantile hemangiomas.
Huang AH; Mannschreck D; Aggarwal P; Mahon M; Cohen BA
Pediatr Dermatol; 2020 Nov; 37(6):1057-1062. PubMed ID: 32869385
[TBL] [Abstract][Full Text] [Related]
19. Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas.
Moyakine AV; Herwegen B; van der Vleuten CJM
J Am Acad Dermatol; 2017 Nov; 77(5):868-873. PubMed ID: 28818436
[TBL] [Abstract][Full Text] [Related]
20. Oral propranolol for infantile hemangiomas beyond the proliferative phase.
Kagami S; Katori T
J Dermatol; 2018 Oct; 45(10):1199-1202. PubMed ID: 30051930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
